Diabetes, hypertension, and chronic kidney disease progression: Role of DPP4

American Journal of Physiology - Renal Physiology

Volumn 312, Issue 4, 2017, Pages F661-F670

  Nistala, Ravi ^a   Savin, Virginia ^b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Albuminuria; Diabetes; Dipeptidyl peptidase 4; Immune

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; CAVEOLIN 1; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER 3;

ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DISEASE COURSE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERTENSION; KIDNEY; KIDNEY FUNCTION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; ANTIGEN PRESENTING CELL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGEN-PRESENTING CELLS; CAVEOLIN 1; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE PROGRESSION; HUMANS; HYPERTENSION; KIDNEY; LYMPHOCYTE ACTIVATION; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; SODIUM-HYDROGEN ANTIPORTER;

EID: 85017013040     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00316.2016     Document Type: Article

References (90)

1. Abd El Motteleb DM, Elshazly SM. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor. Eur J Pharmacol 720: 158-165, 2013. doi: 10.1016/j.ejphar.2013.10.033.
2. Aertgeerts K, Ye S, Shi L, Prasad SG, Witmer D, Chi E, Sang BC, Wijnands RA, Webb DR, Swanson RV. N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding. Protein Sci 13: 145-154, 2004. doi: 10.1110/ps.03352504.
3. Ahrén B. What mediates the benefits associated with dipeptidyl peptidase-IV inhibition? Diabetologia 48: 605-607, 2005. doi: 10.1007/s00125-005-1706-6.
4. Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Klein T, Hocher B. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 36: 119-130, 2012. doi: 10.1159/000341487.
5. α. Am J Physiol Gastrointest Liver Physiol 293: G374-G382, 2007. doi: 10.1152/ajpgi.00128.2007.
6. Aroor A, Zuberek M, Duta C, Meuth A, Sowers JR, Whaley-Connell A, Nistala R. Angiotensin II Stimulation of DPP4 Activity Regulates Megalin in the Proximal Tubules. Int J Mol Sci 17: 17, 2016. doi: 10.3390/ijms17050780.
7. Aroor AR, Habibi J, Ford DA, Nistala R, Lastra G, Manrique C, Dunham MM, Ford KD, Thyfault JP, Parks EJ, Sowers JR, Rector RS. Dipeptidyl peptidase-4 inhibition ameliorates Western diet-induced hepatic steatosis and insulin resistance through hepatic lipid remodeling and modulation of hepatic mitochondrial function. Diabetes 64: 1988-2001, 2015. doi: 10.2337/db14-0804.
8. Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol 188: 5438-5447, 2012. doi: 10.4049/jimmunol.1103801.
9. Boonacker EP, Wierenga EA, Smits HH, Van Noorden CJ. CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. J Histochem Cytochem 50: 1169-1177, 2002. doi: 10.1177/002215540205000903.
10. + exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 297: F1647-F1655, 2009. doi: 10.1152/ajprenal.00082.2009.
11. Chien CH, Tsai CH, Lin CH, Chou CY, Chen X. Identification of hydrophobic residues critical for DPP-IV dimerization. Biochemistry 45: 7006-7012, 2006. doi: 10.1021/bi060401c.
12. Dang DT, Chun SY, Burkitt K, Abe M, Chen S, Havre P, Mabjeesh NJ, Heath EI, Vogelzang NJ, Cruz-Correa M, Blayney DW, Ensminger WD, St Croix B, Dang NH, Dang LH. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res 68: 1872-1880, 2008. doi: 10.1158/0008-5472.CAN-07-1589.
13. Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res 36: 761-765, 2004. doi: 10.1055/s-2004-826160.
14. Dekan G, Miettinen A, Schnabel E, Farquhar MG. Binding of monoclonal antibodies to glomerular endothelium, slit membranes, and epithe- lium after in vivo injection. Localization of antigens and bound IgGs by immunoelectron microscopy. Am J Pathol 137: 913-927, 1990.
15. De Meester I, Korom S, Van Damme J, Scharpé S. CD26, let it cut or cut it down. Immunol Today 20: 367-375, 1999. doi: 10.1016/S0167-5699(99)01486-3.
16. Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care 34, Suppl 2: S276-S278, 2011. doi: 10.2337/dc11-s229.
17. Eun Lee J, Kim JE, Lee MH, Song HK, Ghee JY, Kang YS, Min HS, Kim HW, Cha JJ, Han JY, Han SY, Cha DR. DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury. Lab Invest 96: 547-560, 2016. doi: 10.1038/labinvest.2016.34.
18. Fadini GP, Bonora BM, Cappellari R, Menegazzo L, Vedovato M, Iori E, Marescotti MC, Albiero M, Avogaro A. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes. J Clin Endocrinol Metab 101: 748-756, 2016. doi: 10.1210/jc.2015-3716.
19. Forst T, Michelson G, Diessel S, Jahnke J, Kapitza C. Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients. J Hypertens 34: 345-350, 2016. doi: 10.1097/HJH.0000000000000776.
20. Gekle M. Renal tubule albumin transport. Annu Rev Physiol 67: 573-594, 2005. doi: 10.1146/annurev.physiol.67.031103.154845.
21. Girardi AC, Degray BC, Nagy T, Biemesderfer D, Aronson PS. Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem 276: 46671-46677, 2001. doi: 10.1074/jbc.M106897200.
22. + exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 294: F414-F422, 2008. doi: 10.1152/ajprenal.00174.2007.
23. Glorie LL, Verhulst A, Matheeussen V, Baerts L, Magielse J, Hermans N, D’Haese PC, De Meester I, De Beuf A. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 303: F681-F688, 2012. doi: 10.1152/ajprenal.00075.2012.
24. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, Group TS; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373: 232-242, 2015. doi: 10.1056/NEJMoa1501352.
25. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36: 3460-3468, 2013. doi: 10.2337/dc13-0323.
26. Groop PH, Cooper ME, Perkovic V, Sharma K, Schernthaner G, Haneda M, Hocher B, Gordat M, Cescutti J, Woerle HJ, von Eynatten M. Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial. Diab Vasc Dis Res 12: 455-462, 2015. doi: 10.1177/1479164115579002.
27. Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ. Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53: 730-740, 2010. doi: 10.1007/s00125-009-1643-x.
28. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 58: 69-73, 2011. doi: 10.1507/endocrj.K10E-382.
29. Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, Yokomizo H, Hirata E, Sonoda N, Takayanagi R. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin- induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 61: 1422-1434, 2012. doi: 10.1016/j.metabol.2012.03.002.
30. Herrera C, Morimoto C, Blanco J, Mallol J, Arenzana F, Lluis C, Franco R. Comodulation of CXCR4 and CD26 in human lymphocytes. J Biol Chem 276: 19532-19539, 2001. doi: 10.1074/jbc.M004586200.
31. Higashijima Y, Tanaka T, Yamaguchi J, Tanaka S, Nangaku M. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am J Physiol Renal Physiol 308: F878-F887, 2015. doi: 10.1152/ajprenal.00590.2014.
32. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors-from preclinical development to clinical research. Kidney Blood Press Res 36: 65-84, 2012. doi: 10.1159/000339028.
33. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48: 612-615, 2005. doi: 10.1007/s00125-005-1705-7.
34. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 28: 2221-2228, 2013. doi: 10.1093/ndt/gft029.
35. Johnson RJ, Perez-Pozo SE, Sautin YY, Manitius J, Sanchez-Lozada LG, Feig DI, Shafiu M, Segal M, Glassock RJ, Shimada M, Roncal C, Nakagawa T. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev 30: 96-116, 2009. doi: 10.1210/er.2008-0033.
36. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, Ishigaki Y, Kitada M, Srivastava SP, Koya D. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 63: 2120-2131, 2014. doi: 10.2337/db13-1029.
37. Karalliedde J, Gnudi L. Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrol Dial Transplant 31: 206-213, 2016. doi: 10.1093/ndt/gfu405.
38. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, Simpson JA, Drucker DJ. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 19: 567-575, 2013. doi: 10.1038/nm.3128.
39. Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K, Nakahori Y. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 200: 53-61, 2009. doi: 10.1677/JOE-08-0424.
40. Klemann C, Wagner L, Stephan M, von Hörsten S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4‘s (DPP4) entanglement in the immune system. Clin Exp Immunol 185: 1-21, 2016. doi: 10.1111/cei.12781.
41. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54: 965-978, 2011. doi: 10.1007/s00125-010-2028-x.
42. Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun 443: 828-833, 2014. doi: 10.1016/j.bbrc.2013.12.049.
43. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, Eckardt K, Kaufman JM, Ryden M, Müller S, Hanisch FG, Ruige J, Arner P, Sell H, Eckel J. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60: 1917-1925, 2011. doi: 10.2337/db10-1707.
44. Lee JW, Chou CL, Knepper MA. Deep Sequencing in Microdissected Renal Tubules Identifies Nephron Segment-Specific Transcriptomes. J Am Soc Nephrol 26: 2669-2677, 2015. doi: 10.1681/ASN.2014111067.
45. Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C, Aucouturier P, Moskaug JO, Otto A, Christensen EI, Willnow TE. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 155: 1361-1370, 1999. doi: 10.1016/S0002-9440(10)65238-8.
46. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX, Xu G, Pu Y, Zhu Z, Xu A, Lam KS, Chen ZY, Ng CF, Yao X, Huang Y. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension 60: 833-841, 2012. doi: 10.1161/HYPERTENSIONAHA.112.195115.
47. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, Shao YM, Park TS. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin- induced diabetic rats. J Pharmacol Exp Ther 340: 248-255, 2012. doi: 10.1124/jpet.111.186866.
48. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97: 6874-6879, 2000. doi: 10.1073/pnas.120069197.
49. Matheeussen V, Jungraithmayr W, De Meester I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol Ther 136: 267-282, 2012. doi: 10.1016/j.pharmthera.2012.07.012.
50. Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, Teixeira F, Reis F. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011: 162092, 2011. doi: 10.1155/2011/162092.
51. Miller JC, Brown BD, Shay T, Gautier EL, Jojic V, Cohain A, Pandey G, Leboeuf M, Elpek KG, Helft J, Hashimoto D, Chow A, Price J, Greter M, Bogunovic M, Bellemare-Pelletier A, Frenette PS, Randolph GJ, Turley SJ, Merad M; Immunological Genome Consortium. Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol 13: 888-899, 2012. doi: 10.1038/ni.2370.
52. Min HS, Kim JE, Lee MH, Song HK, Kang YS, Lee MJ, Lee JE, Kim HW, Cha JJ, Chung YY, Hyun YY, Han JY, Cha DR. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Lab Invest 94: 598-607, 2014. doi: 10.1038/labinvest.2014.50.
53. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22: 240-273, 2009. doi: 10.1128/CMR.00046-08.
54. Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35: 992-1019, 2014. doi: 10.1210/er.2014-1035.
55. Muskiet MH, Smits MM, Morsink LM, Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? Nat Rev Nephrol 10: 88-103, 2014. doi: 10.1038/nrneph.2013.272.
56. Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 48: 608-611, 2005. doi: 10.1007/s00125-005-1704-8.
57. Nistala R, Habibi J, Aroor A, Sowers JR, Hayden MR, Meuth A, Knight W, Hancock T, Klein T, Demarco VG, Whaley-Connell A. DPP4 Inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity (Silver Spring) 22: 2172-2179, 2014. doi: 10.1002/oby.20833.
58. Nistala R, Habibi J, Lastra G, Manrique C, Aroor AR, Hayden MR, Garro M, Meuth A, Johnson M, Whaley-Connell A, Sowers JR. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology 155: 2266-2276, 2014. doi: 10.1210/en.2013-1920.
59. Nistala R, Whaley-Connell A. Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II. Mol Cell Endocrinol 378: 53-58, 2013. doi: 10.1016/j.mce.2013.02.005.
60. Norlander AE, Saleh MA, Kamat NV, Ko B, Gnecco J, Zhu L, Dale BL, Iwakura Y, Hoover RS, McDonough AA, Madhur MS. Interleukin-17A Regulates Renal Sodium Transporters and Renal Injury in Angiotensin II-Induced Hypertension. Hypertension 68: 167-174, 2016. doi: 10.1161/HYPERTENSIONAHA.116.07493.
61. Odoni G, Ritz E. Diabetic nephropathy-what have we learned in the last three decades? J Nephrol 12, Suppl 2: S120-S124, 1999.
62. Ohnuma K, Dang NH, Morimoto C. Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol 29: 295-301, 2008. doi: 10.1016/j.it.2008.02.010.
63. Ohnuma K, Yamochi T, Uchiyama M, Nishibashi K, Yoshikawa N, Shimizu N, Iwata S, Tanaka H, Dang NH, Morimoto C. CD26 upregulates expression of CD86 on antigen-presenting cells by means of caveolin-1. Proc Natl Acad Sci USA 101: 14186-14191, 2004. doi: 10.1073/pnas.0405266101.
64. Ott C, Kistner I, Keller M, Friedrich S, Willam C, Bramlage P, Schmieder RE. Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia 59: 2579-2587, 2016. doi: 10.1007/s00125-016-4083-4.
65. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18: 1227-1238, 2007. doi: 10.1681/ASN.2006070778.
66. Peck KM, Cockrell AS, Yount BL, Scobey T, Baric RS, Heise MT. Glycosylation of mouse DPP4 plays a role in inhibiting Middle East respiratory syndrome coronavirus infection. J Virol 89: 4696-4699, 2015. doi: 10.1128/JVI.03445-14.
67. Proost P, Struyf S, Schols D, Durinx C, Wuyts A, Lenaerts JP, De Clercq E, De Meester I, Van Damme J. Processing by CD26/dipeptidylpeptidase IV reduces the chemotactic and anti-HIV-1 activity of stromalcell- derived factor-1alpha. FEBS Lett 432: 73-76, 1998. doi: 10.1016/S0014-5793(98)00830-8.
68. Ravi Nistala AA, Meuth A, Sowers J, Whaley-Connell A, Bender S, Mckarns S. DPP4 inhibition substantially reverses Ang II-mediated inflammation and kidney injury independent of BP reduction. Hypertension 63: A030, 2014.
69. Rinkevich Y, Walmsley GG, Hu MS, Maan ZN, Newman AM, Drukker M, Januszyk M, Krampitz GW, Gurtner GC, Lorenz HP, Weissman IL, Longaker MT. Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science 348: aaa2151, 2015. doi: 10.1126/science.aaa2151.
70. Röhrborn D, Wronkowitz N, Eckel J. DPP4 in Diabetes. Front Immunol 6: 386, 2015. doi: 10.3389/fimmu.2015.00386.
71. Rubio-Aliaga I, Frey I, Boll M, Groneberg DA, Eichinger HM, Balling R, Daniel H. Targeted disruption of the peptide transporter Pept2 gene in mice defines its physiological role in the kidney. Mol Cell Biol 23: 3247-3252, 2003. doi: 10.1128/MCB.23.9.3247-3252.2003.
72. Sadir R, Imberty A, Baleux F, Lortat-Jacob H. Heparan sulfate/heparin oligosaccharides protect stromal cell-derived factor-1 (SDF-1)/CXCL12 against proteolysis induced by CD26/dipeptidyl peptidase IV. J Biol Chem 279: 43854-43860, 2004. doi: 10.1074/jbc.M405392200.
73. Safwan Hyder CM, Mugerfeld I, Habibi J, Whaley-Connell A, Sowers JR, Nistala R. Angiotensin-II Activation of Na+/H+ Exchanger-3 and mTORC1 in the Proximal Tubule Is Suppressed by Dipeptidyl Peptidase-4 Inhibitor. Endocr Rev SAT-LB18, 2013.
74. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317-1326, 2013. doi: 10.1056/NEJMoa1307684.
75. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA, Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R, Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL; SAVOR-TIMI 53 Steering Committee and Investigators*. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130: 1579-1588, 2014. doi: 10.1161/CIRCULATIONAHA.114.010389.
76. Sharkovska Y, Reichetzeder C, Alter M, Tsuprykov O, Bachmann S, Secher T, Klein T, Hocher B. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J Hypertens 32: 2211-2223, 2014. doi: 10.1097/HJH.0000000000000328.
77. Shubrook J, Colucci R, Guo A, Schwartz F. Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Clin Med Insights Endocrinol Diabetes 4: 1-12, 2011. doi: 10.4137/CMED.S5114.
78. Silbernagl S, Ganapathy V, Leibach FH. H+ gradient-driven dipeptide reabsorption in proximal tubule of rat kidney. Studies in vivo and in vitro. Am J Physiol Renal Fluid Electrolyte Physiol 253: F448-F457, 1987.
79. Smits MM, Tonneijck L, Muskiet MH, Hoekstra T, Kramer MH, Pieters IC, Cahen DL, Diamant M, van Raalte DH. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open 5: e009579, 2015. doi: 10.1136/bmjopen-2015-009579.
80. Tagore DM, Nolte WM, Neveu JM, Rangel R, Guzman-Rojas L, Pasqualini R, Arap W, Lane WS, Saghatelian A. Peptidase substrates via global peptide profiling. Nat Chem Biol 5: 23-25, 2009. doi: 10.1038/nchembio.126.
81. Takahashi R, Toyoda E, Aoki Y, Suzuki KT, Goto S. Paradoxical increase of heat-shock response with age in a substrain of F344 rats: comparison between F344/DuCrj and F344/Jcl. Mech Ageing Dev 123: 1605-1615, 2002. doi: 10.1016/S0047-6374(02)00096-9.
82. Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang NH, Morimoto C. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun 401: 7-12, 2010. doi: 10.1016/j.bbrc.2010.08.112.
83. Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 90: 4586-4590, 1993. doi: 10.1073/pnas.90.10.4586.
84. Tinoco AD, Tagore DM, Saghatelian A. Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform. J Am Chem Soc 132: 3819-3830, 2010. doi: 10.1021/ja909524e.
85. Tiruppathi C, Miyamoto Y, Ganapathy V, Roesel RA, Whitford GM, Leibach FH. Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IVDPP4 positive and dipeptidyl peptidase IV-negative rat strains. J Biol Chem 265: 1476-1483, 1990.
86. Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O, Steg PG, Davidson JA, Nicolau JC, Corbalan R, Hirshberg B, Frederich R, Im K, Umez-Eronini AA, He P, McGuire DK, Leiter LA, Raz I, Scirica BM; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVORTIMI 53 Trial. Diabetes Care 38: 696-705, 2015. doi: 10.2337/dc14-1850.
87. Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 33: 1519-1527, 2003. doi: 10.1002/eji.200323469.
88. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, Roman RJ. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 21: 1125-1135, 2003. doi: 10.1097/00004872-200306000-00012.
89. Zhong J, Rao X, Deiuliis J, Braunstein Z, Narula V, Hazey J, Mikami D, Needleman B, Satoskar AR, Rajagopalan S. A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation. Diabetes 62: 149 -157, 2013. doi: 10.2337/db12-0230.
90. Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 226: 305-314, 2013. doi: 10.1016/j.atherosclerosis.2012.09.012.